Abstract
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Arthritis, Rheumatoid / drug therapy
-
Cell Death / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cisplatin / adverse effects
-
DNA / metabolism
-
Drug Design
-
Drug Resistance, Neoplasm
-
Drug Screening Assays, Antitumor
-
Humans
-
Kidney / drug effects
-
Organogold Compounds / chemistry
-
Organogold Compounds / metabolism
-
Organogold Compounds / pharmacology*
-
Proteasome Inhibitors
-
Reactive Oxygen Species / metabolism
-
Solubility
-
Thiocarbamates / chemistry
-
Thiocarbamates / pharmacology*
-
Thioredoxin-Disulfide Reductase / antagonists & inhibitors
-
Ubiquitin / antagonists & inhibitors
Substances
-
Antineoplastic Agents
-
Organogold Compounds
-
Proteasome Inhibitors
-
Reactive Oxygen Species
-
Thiocarbamates
-
Ubiquitin
-
DNA
-
Thioredoxin-Disulfide Reductase
-
Cisplatin